{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:09:42Z","timestamp":1790964582701,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["19-06199S"],"award-info":[{"award-number":["19-06199S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["IGA_LF_2021_013"],"award-info":[{"award-number":["IGA_LF_2021_013"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of empagliflozin (10 mg\/kg\/day for eight weeks) on the development of NAFLD and its complications using HHTg rats as a non-obese prediabetic rat model. Empagliflozin treatment reduced neutral triacylglycerols and lipotoxic diacylglycerols in the liver and was accompanied by significant changes in relative mRNA expression of lipogenic enzymes (Scd-1, Fas) and transcription factors (Srebp1, Ppar\u03b3). In addition, alterations in the gene expression of cytochrome P450 proteins, particularly Cyp2e1 and Cyp4a, together with increased Nrf2, contributed to the improvement of hepatic lipid metabolism after empagliflozin administration. Decreased circulating levels of fetuin-A improved lipid metabolism and attenuated insulin resistance in the liver and in peripheral tissues. Our results highlight the beneficial effect of empagliflozin on hepatic lipid metabolism and lipid accumulation independent of obesity, with the mechanisms understood to involve decreased lipogenesis, alterations in cytochrome P450 proteins, and decreased fetuin-A. These changes help to alleviate NAFLD symptoms in the early phase of the disease and before the onset of diabetes.<\/jats:p>","DOI":"10.3390\/ijms222111513","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:54:33Z","timestamp":1635292473000},"page":"11513","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia"],"prefix":"10.3390","volume":"22","author":[{"given":"Martina","family":"H\u00fcttl","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-7636","authenticated-orcid":false,"given":"Irena","family":"Markova","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Miklankova","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-8848","authenticated-orcid":false,"given":"Iveta","family":"Zapletalova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-4971","authenticated-orcid":false,"given":"Martin","family":"Poruba","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-6888","authenticated-orcid":false,"given":"Martin","family":"Haluzik","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1852-924X","authenticated-orcid":false,"given":"Ivana","family":"Van\u011b\u010dkova","sequence":"additional","affiliation":[{"name":"Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, 14220 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Malinska","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3350\/cmh.2020.0137","article-title":"Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease","volume":"26","author":"Kim","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1530\/EJE-13-0296","article-title":"Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders","volume":"169","author":"Hazlehurst","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","article-title":"Nonobese Fatty Liver Disease","volume":"15","author":"Kim","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","article-title":"The Pleiotropic Effects of Sodium\u2013Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/5584_2020_479","article-title":"Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"1307","author":"Kuchay","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., and Targher, G. (2020). Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11010022"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N., Nikolopoulou, C., Papoutsi, K., Kyrou, I., Mantzoros, C.S., Kyriakopoulos, G., Chatzigeorgiou, A., Kalotychou, V., Randeva, M.S., and Chatha, K. (2021). Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((\u2212\/\u2212)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020818"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Perakakis, N., Chrysafi, P., Feigh, M., Veidal, S., and Mantzoros, C. (2021). Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126332"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.33549\/physiolres.930000.55.S1.49","article-title":"Hereditary hypertriglyceridemic rat: A suitable model of cardiovascular disease and metabolic syndrome?","volume":"55","author":"Zicha","year":"2006","journal-title":"Physiol. Res."},{"key":"ref_15","first-page":"2579","article-title":"The hereditary hypertriglyceridemic nonobese rat: An experimental model of human hypertriglyceridemia","volume":"22","year":"1990","journal-title":"Transplant. Proc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metab. Clin. Exp."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy Balance After Sodium\u2013Glucose Cotransporter 2 Inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1002\/jcb.28141","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes","volume":"120","author":"Kim","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112246","DOI":"10.1016\/j.biopha.2021.112246","article-title":"Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension","volume":"144","author":"Behuliak","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12576-010-0127-6","article-title":"Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats","volume":"61","author":"Iwata","year":"2011","journal-title":"J. Physiol. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.coph.2020.10.016","article-title":"The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes","volume":"55","author":"Guerra","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_25","first-page":"16687","article-title":"The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Pokharel","year":"2021","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-018-0090-1","article-title":"DHA and 19,20-EDP induce lysosomal-proteolytic-dependent cytotoxicity through de novo ceramide production in H9c2 cells with a glycolytic profile","volume":"4","author":"Endo","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bdd.2153","article-title":"Metabolism of steroids by cytochrome P450 2C9 variants","volume":"39","author":"Uno","year":"2018","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.biochi.2004.09.018","article-title":"SREBP transcription factors: Master regulators of lipid homeostasis","volume":"86","author":"Hegarty","year":"2004","journal-title":"Biochimie"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/597134","article-title":"The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism","volume":"2015","author":"Chambel","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","article-title":"A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111326","DOI":"10.1016\/j.biopha.2021.111326","article-title":"New insight and potential therapy for NAFLD: CYP2E1 and flavonoids","volume":"137","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Harjum\u00e4ki, R., Pridgeon, C., and Ingelman-Sundberg, M. (2021). CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158221"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","article-title":"CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease","volume":"58","author":"Leung","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13036-019-0198-8","article-title":"Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model","volume":"13","author":"Ryu","year":"2019","journal-title":"J. Biol. Eng."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1073\/pnas.1700172114","article-title":"Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","first-page":"595","article-title":"Cytochrome P450 1A1 (CYP1A1) Catalyzes Lipid Peroxidation of Oleic Acid-Induced HepG2 Cells","volume":"83","author":"Huang","year":"2018","journal-title":"Biochemistry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dogru, T., Kirik, A., Gurel, H., Rizvi, A., Rizzo, M., and Sonmez, A. (2021). The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126627"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/187221411799015372","article-title":"Fetuin-A: A multifunctional protein","volume":"5","author":"Mori","year":"2011","journal-title":"Recent Pat. Endocr. Metab. Immune Drug Discov."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bcp.2019.05.011","article-title":"Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice","volume":"166","author":"Lee","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2478\/jtim-2019-0029","article-title":"Role of hepatokines in non-alcoholic fatty liver disease","volume":"7","author":"Ke","year":"2019","journal-title":"J. Transl. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2019.08.005","article-title":"Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease","volume":"498","author":"Su","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.redox.2013.12.025","article-title":"Possible involvement of nuclear factor erythroid 2-related factor 2 in the gene expression of Cyp2b10 and Cyp2a5","volume":"2","author":"Ashino","year":"2014","journal-title":"Redox Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"117908","DOI":"10.1016\/j.lfs.2020.117908","article-title":"Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-\u03baB\/Nrf-2\/PPAR-\u03b3 interplay in mice","volume":"256","author":"Abdelhamid","year":"2020","journal-title":"Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.nut.2015.03.011","article-title":"Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia","volume":"31","author":"Malinska","year":"2015","journal-title":"Nutrition"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11513\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:28Z","timestamp":1760167408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":48,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111513"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111513","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}